Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (VVOS) priced its initial public offering on Dec 14, 2020 at $6.00 per share, within its $5.00–$7.00 range, raising $21M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $106M. Roth Capital was lead-left underwriter, joined by Craig-Hallum. Ellenoff Grossman & Schole advised the company and Dorsey & Whitney advised the underwriters.

Vivos Therapeutics, Inc. is a revenue-stage medical technology company offering a non-surgical, non-invasive, non-pharmaceutical treatment for sleep disordered breathing, including mild-to-moderate obstructive sleep apnea. Its products also address certain craniofacial and anatomical anomalies linked to the condition, as an alternative to CPAP.

Status

IPO

Ticker

VVOS

Exchange

Nasdaq Capital Market

Priced

Dec 14, 2020

IPO price

$6.00

Price range

$5.00–$7.00

Raised

$21M

Market cap at IPO price

$106M

First filed

Oct 9, 2020

Underwriters

Roth Capital and Craig-Hallum

Company counsel

Ellenoff Grossman & Schole

Underwriters' counsel

Dorsey & Whitney

Sector

Healthcare

Country / state

CO

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.